Claude

Know the Business

Religare Enterprises is a holding company whose entire investment case rests on one asset: Care Health Insurance, India's second-largest standalone health insurer (SAHI) with ~22% SAHI market share and ₹9,200+ Cr. GWP in FY25. Everything else – broking (Religare Broking), MSME lending (Religare Finvest), affordable housing (RHDFCL) – is either subscale, loss-making, or just emerging from years of regulatory lockdown. The market is likely underestimating how long it takes to rebuild three broken financial services franchises under a new promoter, and overestimating the near-term earnings power of the consolidated entity.

How This Business Actually Works

Care Health Insurance is the economic engine. It collects health insurance premiums (GWP ~₹9,200 Cr. in FY25, growing ~30% CAGR), invests the float (~₹10,200 Cr. AUM at 7.3% yield), and earns the spread between investment income plus premiums minus claims and operating expenses. The combined ratio hovers around 101-111% – meaning underwriting alone is roughly breakeven – so investment income is the actual profit driver.

The holding company (REL) itself is an RBI-registered Core Investment Company that owns 63.2% of Care Health, 100% of Religare Broking, 100% of Religare Finvest, and 87.5% of RHDFCL (through RFL). REL earns almost nothing standalone – its revenue is negligible, and it exists primarily as a vehicle to hold and fund subsidiaries.

The cost structure is dominated by insurance claims (~65-75% claims ratio at Care Health), followed by employee expenses and distribution commissions. Interest expense has collapsed from ₹1,580 Cr. in FY2014 to ₹63 Cr. in FY2025 as legacy debt was cleared – this deleveraging is the single most important financial development in the last five years.

The critical bottleneck is capital. REL raised ₹1,500 Cr. via preferential warrants in H2 FY26, and the Burman Group (promoter since Feb 2025) contributed ₹750 Cr. of that. This capital is being deployed across subsidiaries – Care Health needs it for solvency and growth, RFL needs it to restart lending, RHDFCL needs it to scale. Without continued capital infusion, growth across all subsidiaries stalls.

Care Health's retail market share among SAHIs has surged from 13.9% in FY22 to 19.5% in 9M FY26. Proprietary business grew 41% YoY in Q3 FY26. The credit rating was upgraded from A+ to AA- in Q3 FY26, reducing cost of doing business. This is the one part of Religare that is genuinely winning.

The Playing Field

Religare trades at 73x earnings with a 5% ROE – the worst return-for-valuation trade-off in the peer set. This pricing reflects a bet on the future, not the present. Motilal Oswal (25% ROE at 23x PE) and 360 ONE (21% ROE at 35x PE) show what "good" looks like in diversified financials: high-ROE businesses with operating leverage. Religare's broking arm is a fraction of Motilal's scale and profitability, and its lending business is just restarting from zero.

The closest structural peer is Edelweiss, which also pivoted from a troubled diversified financial services past toward insurance (Niva Bupa). But Edelweiss has further de-risked by selling its wealth management business and focusing sharply, while Religare is trying to rebuild all four verticals simultaneously.

Aditya Birla Capital is the scale comparison – 12x Religare's market cap with a genuine multi-vertical platform. It demonstrates the difficulty: even with massive capital backing from the Birla Group, ABC Capital trades at modest multiples because conglomerate discounts are real in Indian financial services.

Is This Business Cyclical?

The cyclicality differs sharply by subsidiary:

The real cycle risk at Religare is not macro – it is regulatory and governance-driven. The company went through a near-death experience from FY2018-FY2022 when the erstwhile Singh promoters siphoned ₹2,037 Cr. through the corporate loan book, RBI imposed a Corrective Action Plan on RFL, banks classified RFL as fraud, and operating losses mounted. Revenue collapsed from ₹4,895 Cr. (FY16) to ₹2,371 Cr. (FY19). This was not a business cycle – it was a governance crisis.

FY2023's profit spike (₹3,259 Cr. PBT) was a one-off driven by ₹3,473 Cr. in "other income" – likely related to debt restructuring / fair value gains. Normalized profitability in FY2024-25 is ₹243-448 Cr. PBT, almost entirely from Care Health's insurance operations.

Care Health's combined ratio rose from 101.1% (H1 FY25) to 109.6% (9M FY26 on 1/n basis), with Q3 FY26 at 111.1%. The claims ratio jump from 66.7% to 73.8% signals that rapid growth is pulling in higher-cost risks and that normalization is ongoing. This is the most important short-term metric to watch.

The Metrics That Actually Matter

Care Health GWP Growth – This single metric drives 85%+ of Religare's enterprise value. Care is growing faster than the SAHI industry (19.5% industry share vs. 14.3% two years ago). If this decelerates below 20%, the premium valuation evaporates.

Combined Ratio – Care's combined ratio at 109.6% in 9M FY26 means it is losing money on underwriting and relying on investment income for profit. The ratio must trend toward 100% as scale builds. The Q3 FY26 spike to 111% (partly due to new wage code impact of ₹13.5 Cr.) needs monitoring.

Care Solvency Ratio – At 1.70x, solvency is above the 1.5x regulatory minimum but has compressed from 1.89x in Q2 FY26. Fast GWP growth consumes solvency capital. If solvency drops below 1.6x, either growth must slow or REL must inject more equity.

RFL AUM Rebuild – RFL had its CAP removed only in July 2025. Net AUM is just ₹70 Cr. Rebuilding a credible MSME lending book will take 3-5 years. The pace of disbursement is the leading indicator of whether RFL becomes a real business or remains a dormant shell.

Holding Company Discount – REL's stake in Care Health alone (63.2% of a business with ₹2,587 Cr. net worth and ₹10,000+ Cr. GWP run-rate) likely exceeds REL's current market cap. The announced demerger into two listed entities (insurance-focused REL + financial services RFL) is the key catalyst to narrow this discount.

What I'd Tell a Young Analyst

The only question that matters: is Care Health Insurance worth the price of admission? Everything else – broking, lending, housing finance – is noise for at least the next 2-3 years.

The demerger announced in February 2026 is the structural catalyst. Post-demerger, REL retains Care Health (insurance) and RFL lists separately with broking, lending, and housing. If the market re-rates Care Health as a standalone health insurance compounder at SAHI-peer multiples (Star Health trades at 30-40x earnings), the value unlock could be material.

Watch three things. First, Care Health's combined ratio trajectory – if it stays above 105% for two more quarters, the "profitable compounder" narrative weakens. Second, the Burman Group's capital commitment – they have put in ₹750 Cr. and need to convert warrants worth another ₹750 Cr.; any hesitation signals problems. Third, RFL's lending restart – if disbursements do not meaningfully ramp by FY27, the "financial services" entity post-demerger will be a hollow shell.

The biggest risk nobody talks about: the Daiichi Sankyo litigation overhang. The erstwhile promoter group's legal battle with Daiichi has produced a status quo order on the "Religare" brand itself. If the brand ends up contested or encumbered, it complicates the demerger and the identity of the entire group.